These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7665845)

  • 1. Perspectives in the treatment of liver fibrosis.
    Mavier P; Mallat A
    J Hepatol; 1995; 22(2 Suppl):111-5. PubMed ID: 7665845
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogenesis, experimental manipulation and treatment of liver fibrosis.
    Arthur MJ
    Exp Nephrol; 1995; 3(2):90-5. PubMed ID: 7773644
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutical targets for revert liver fibrosis].
    García B L; Gálvez G J; Armendáriz B J
    Rev Med Chil; 2007 Jun; 135(6):783-91. PubMed ID: 17728907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
    Castilla A; Prieto J; Fausto N
    N Engl J Med; 1991 Apr; 324(14):933-40. PubMed ID: 1900574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats.
    Lang Q; Liu Q; Xu N; Qian KL; Qi JH; Sun YC; Xiao L; Shi XF
    Biochem Biophys Res Commun; 2011 Jun; 409(3):448-53. PubMed ID: 21600192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis.
    Liu X; Hu H; Yin JQ
    Liver Int; 2006 Feb; 26(1):8-22. PubMed ID: 16420505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis.
    Eghbali-Fatourechi G; Sieck GC; Prakash YS; Maercklein P; Gores GJ; Fitzpatrick LA
    Endocrinology; 1996 May; 137(5):1894-903. PubMed ID: 8612529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta signaling and cirrhosis.
    Wrana JL
    Hepatology; 1999 Jun; 29(6):1909-10. PubMed ID: 10347138
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.
    Nakamura T; Sakata R; Ueno T; Sata M; Ueno H
    Hepatology; 2000 Aug; 32(2):247-55. PubMed ID: 10915731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Persectives on postgenome medicine: Gene therapy for liver cirrhosis].
    Ueki T; Okamoto E; Takeuchi M; Fujimoto J
    Nihon Rinsho; 2001 Jan; 59(1):152-6. PubMed ID: 11197847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Ito cell proliferation by soluble factors.
    Rosenbaum J; Blazejewski S
    J Hepatol; 1995; 22(2 Suppl):65-70. PubMed ID: 7545195
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease.
    Bian Z; Miao Q; Zhong W; Zhang H; Wang Q; Peng Y; Chen X; Guo C; Shen L; Yang F; Xu J; Qiu D; Fang J; Friedman S; Tang R; Gershwin ME; Ma X
    J Autoimmun; 2015 Sep; 63():76-87. PubMed ID: 26238209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.
    Inagaki Y; Okazaki I
    Gut; 2007 Feb; 56(2):284-92. PubMed ID: 17303605
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fibrogenesis and fibrolysis in the liver].
    Herbst H; Schuppan D; Milani S
    Verh Dtsch Ges Pathol; 1995; 79():15-27. PubMed ID: 8600680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
    Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic fibrosis--new therapeutic approaches.
    Schiff ER
    N Engl J Med; 1991 Apr; 324(14):987-9. PubMed ID: 2002822
    [No Abstract]   [Full Text] [Related]  

  • 17. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis.
    Uchio K; Graham M; Dean NM; Rosenbaum J; Desmoulière A
    Wound Repair Regen; 2004; 12(1):60-6. PubMed ID: 14974966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.
    Edgley AJ; Krum H; Kelly DJ
    Cardiovasc Ther; 2012 Feb; 30(1):e30-40. PubMed ID: 21883991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy.
    Inagaki Y; Higashiyama R; Higashi K
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2():85-8. PubMed ID: 22320923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts.
    Sheppard D
    Ann Am Thorac Soc; 2015 Mar; 12 Suppl 1(Suppl 1):S21-3. PubMed ID: 25830829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.